Profile data is unavailable for this security.
About the company
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
- Revenue in CHF (TTM)605.26m
- Net income in CHF120.25m
- Incorporated1971
- Employees2.21k
- LocationBachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
- Phone+41 619352333
- Fax+41 619352324
- Websitehttps://www.bachem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuros Biosciences AG | 69.15m | -3.43m | 1.12bn | 122.00 | -- | 21.22 | -- | 16.27 | -0.096 | -0.1102 | 2.37 | 1.38 | 0.9653 | 1.91 | 7.68 | 566,778.10 | -4.78 | -10.85 | -5.94 | -12.28 | 82.04 | 84.11 | -4.95 | -31.80 | 1.69 | -- | 0.0777 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| BioArctic AB | 125.12m | 74.38m | 1.17bn | 116.00 | 18.85 | 8.80 | 13.91 | 9.39 | 10.20 | 10.20 | 17.16 | 21.85 | 0.931 | -- | -- | 14,180,610.00 | 55.34 | -2.87 | 60.55 | -3.22 | 97.61 | 86.59 | 59.44 | -12.41 | -- | -- | 0.0257 | -- | -58.22 | -1.80 | -177.24 | -- | 52.19 | -- |
| Evotec SE | 735.37m | -193.10m | 1.23bn | 4.77k | -- | 1.44 | -- | 1.67 | -1.17 | -1.17 | 4.44 | 5.14 | 0.3795 | 20.84 | 4.29 | 163,293.80 | -9.97 | -2.40 | -12.34 | -2.87 | 13.62 | 21.49 | -26.26 | -6.78 | 1.93 | -2.03 | 0.3442 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Galapagos NV | 275.64m | -167.31m | 1.63bn | 704.00 | -- | 0.6369 | -- | 5.92 | -2.72 | -2.57 | 4.48 | 41.70 | 0.0705 | 0.7734 | 5.59 | 419,666.20 | -4.28 | -2.04 | -4.74 | -2.28 | 84.42 | -- | -60.70 | -27.56 | 7.86 | -- | 0.0039 | -- | 14.99 | -20.82 | 67.85 | -- | 12.44 | -- |
| Genus plc | 724.91m | -4.32m | 1.72bn | 3.44k | -- | 3.09 | 40.56 | 2.38 | -0.0612 | -0.0612 | 10.16 | 7.82 | 0.6585 | -- | 6.11 | 195,289.30 | -0.6275 | 3.30 | -0.7199 | 3.87 | -- | -- | -0.953 | 4.98 | 1.33 | -- | 0.3656 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| BB BIOTECH AG | 69.17m | -425.53m | 1.83bn | 86.00 | -- | 0.9268 | -- | 26.39 | -7.78 | -7.78 | 1.26 | 35.55 | 0.029 | -- | 5.61 | 804,244.20 | -17.82 | -1.24 | -19.26 | -1.35 | 94.80 | 97.19 | -615.24 | -39.47 | -- | 0.0771 | 0.00 | -- | 21,076.79 | -31.20 | 136.74 | -35.45 | -- | -11.94 |
| Zealand Pharma A/S | 6.96m | -148.20m | 3.20bn | 385.00 | -- | 3.06 | -- | 460.13 | -17.30 | -17.30 | 0.811 | 117.53 | 0.0088 | 0.5409 | 0.7554 | 166,250.80 | -18.66 | -32.33 | -19.63 | -36.49 | 93.39 | 95.31 | -2,128.64 | -515.03 | 25.07 | -- | 0.0453 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| BACHEM HOLDING AG | 605.26m | 120.25m | 4.35bn | 2.21k | 36.13 | 3.13 | 26.63 | 7.19 | 1.61 | 1.61 | 8.07 | 18.55 | 0.3357 | 1.07 | 2.91 | 274,245.10 | 6.67 | 8.26 | 7.61 | 9.44 | 30.16 | 31.55 | 19.87 | 20.06 | 1.33 | -- | 0.0002 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Qiagen NV | 1.61bn | 75.37m | 8.41bn | 5.70k | 119.05 | 3.07 | 36.46 | 5.22 | 0.3502 | 0.3502 | 7.87 | 13.57 | 0.3529 | 2.11 | 5.64 | 299,628.60 | 1.65 | 5.76 | 1.91 | 6.88 | 64.09 | 64.31 | 4.68 | 16.85 | 2.83 | -- | 0.2924 | -- | 0.6565 | 5.32 | -75.51 | -- | -9.03 | -- |
| Eurofins Scientific SE | 6.48bn | 591.96m | 10.31bn | 62.70k | 18.58 | 2.12 | 8.60 | 1.59 | 3.26 | 1.81 | 35.74 | 28.58 | 0.6384 | 38.44 | 5.00 | 110,868.30 | 6.31 | 7.65 | 7.88 | 9.53 | 22.33 | 23.95 | 9.88 | 11.41 | 1.09 | 7.95 | 0.4014 | 23.54 | 6.70 | 8.78 | 22.85 | 15.36 | 4.45 | -- |
| Genmab A/S | 2.60bn | 912.53m | 11.43bn | 2.64k | 12.54 | 2.65 | 11.75 | 4.40 | 113.70 | 113.70 | 323.83 | 538.06 | 0.5434 | 11.54 | 4.38 | 7,754,022.00 | 19.07 | 17.70 | 21.13 | 19.07 | 95.12 | -- | 35.10 | 35.77 | 5.32 | -- | 0.0263 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
Data as of Jul 18 2025. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF
11.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 1.99m | 2.65% |
| VV Verm�gensverwaltung AGas of 30 Apr 2025 | 1.18m | 1.57% |
| UBS Asset Management Switzerland AGas of 30 Jun 2025 | 1.14m | 1.52% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 1.12m | 1.49% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 773.91k | 1.03% |
| Z�rcher Kantonalbank (Investment Management)as of 30 May 2025 | 580.54k | 0.77% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 472.84k | 0.63% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 451.01k | 0.60% |
| Juno Investment Partnersas of 31 Mar 2025 | 390.47k | 0.52% |
| GAM Investment Management (Switzerland) AGas of 31 Mar 2025 | 367.97k | 0.49% |
More ▼
Data from 31 Dec 2024 - 30 Apr 2025Source: FactSet Research Systems Inc.
